Posted in

Revolutionizing Treatment: India’s First Methotrexate Oral Solution

•Posted inMedical Updates
Doctor reviewing diabetes patient chart while learning diabetology through an online course

Beta Drugs Limited, a prominent manufacturer of oncology medicines in India, proudly announces a significant milestone: the Drug Controller General of India (DCGI) has granted approval for their Methotrexate Solution for Oral Use. This landmark approval establishes Beta Drugs Limited as the first Indian company to introduce a Methotrexate Oral Solution to the market, providing a much-needed patient-friendly and bioequivalent alternative to existing tablet forms.

Key Advantages of Methotrexate Oral Solution

Methotrexate is a globally recognized therapy for various oncology and autoimmune disorders. Traditionally, this medication has been available as tablets or injections. These forms often present challenges in accurate dosing and convenient administration, particularly for pediatric, geriatric, and chronic-care patients. Consequently, the new oral solution offers an easy-to-administer, precisely dosed, and bioequivalent option, thereby significantly enhancing patient compliance, convenience, and safety under proper medical supervision.

Moreover, the oral solution format ensures consistent absorption, which is crucial for therapeutic effectiveness. This development represents a substantial advancement in drug delivery, especially for patients who struggle with swallowing pills or require highly precise dosages. Furthermore, it can simplify the treatment regimen, leading to better adherence and improved clinical outcomes.

Therapeutic Indications and Expanded Access

The approved Methotrexate Oral Solution is indicated for a wide range of conditions. This includes acute lymphoblastic leukemia (ALL), lymphomas, and various solid tumors. Additionally, it is approved for autoimmune diseases such as Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), and Psoriasis Vulgaris, encompassing Chronic Plaque Psoriasis, Erythrodermic Psoriasis, Psoriatic Arthritis, and Pustular Psoriasis.

This first-to-market approval marks a major strategic expansion for Beta Drugs Limited, moving beyond its strong presence in oncology into the autoimmune therapy segments. The introduction of this oral solution creates new opportunities within the pediatric, hospital, and chronic-care sectors. Ultimately, this initiative underscores Beta Drugs Limited’s commitment to developing differentiated, patient-centric solutions that improve treatment access and enhance the quality of life for many patients across India.

Frequently Asked Questions

Q1: What makes Methotrexate Oral Solution a significant development for patients?

The Methotrexate Oral Solution offers a patient-friendly, easy-to-administer, and accurately dosed alternative to traditional tablets or injections. This is particularly beneficial for pediatric, geriatric, and chronic-care patients, improving compliance and convenience.

Q2: What conditions can be treated with Beta Drugs Limited’s Methotrexate Oral Solution?

The oral solution is indicated for acute lymphoblastic leukemia (ALL), lymphomas, various solid tumors, Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), and several forms of Psoriasis Vulgaris, including Chronic Plaque Psoriasis and Psoriatic Arthritis.

Q3: How does this approval impact Beta Drugs Limited’s market position?

This approval makes Beta Drugs Limited the first Indian company to launch Methotrexate Oral Solution, signifying a major step in expanding its portfolio beyond oncology into autoimmune therapy. It also strengthens the company’s leadership in both oncology and dermatology segments.

References

  1. Beta Drugs Limited Becomes the First Indian Company to Receive Approval forMethotrexate Oral Solution – ETHealthworld
  2. Beta Drugs’ Methotrexate Oral Solution Gets SEC Manufacturing, Marketing Nod. Medical Dialogues. https://medicaldialogues.in/news/pharma/beta-drugs-methotrexate-oral-solution-gets-sec-manufacturing-marketing-nod-117565. Accessed October 23, 2025.
  3. Methotrexate Oral Solution. Chemocare. https://chemocare.com/chemotherapy/drug-info/Methotrexate-Oral-Solution.aspx. Accessed October 23, 2025.
  4. methotrexate 2.5 mg/mL oral solution. Kaiser Permanente. https://healthy.kaiserpermanente.org/health-wellness/drug-encyclopedia/drug.methotrexate-25-mg-ml-oral-solution.889047. Accessed October 23, 2025.
  5. Beta Drugs Ltd. Screener. https://www.screener.in/company/BETADRUGS/consolidated/. Accessed October 23, 2025.
  6. Methotrexate (oral route) – Side effects & dosage – Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/methotrexate-oral-route/side-effects/drg-20067644. Accessed October 23, 2025.
  7. Methotrexate | Side Effects, Dosage, Uses, and More – Healthline. https://www.healthline.com/health/methotrexate-oral-solution. Accessed October 23, 2025.

Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.